Lipemia retinalis following FLAG-Ida protocol in an 11-year-old patient with acute myeloid leukemia

被引:0
|
作者
Koruk, Reyhan Hazal Kaplan [1 ]
Kocabora, Mehmet Selim [2 ]
Erdur, Sevil Karaman [2 ]
Yaman, Yontem [3 ]
机构
[1] Istanbul Training & Res Hosp, Dept Ophthalmol, Org Abdurrahman Nafiz Gurman St 24, TR-34098 Istanbul, Turkiye
[2] Istanbul Medipol Univ, Fac Med, Dept Ophthalmol, Istanbul, Turkiye
[3] Istanbul Medipol Univ, Fac Med, Dept Pediat Hematol & Oncol, Istanbul, Turkiye
关键词
Vitreous/retinal disease; PEDIATRIC OPHTHALMOLOGY; pharmacology; PHARMACOLOGY; practice management; SOCIOECONOMICS AND EDUCATION IN MEDICINE/OPHTHALMOLOGY; systemic drug retinal toxicity; RETINA; retinal pathology / research; AML; FLAG-Ida; hypertriglyceridemia; hypercholesterolemia; leukemia; lipemia retinalis;
D O I
10.1177/11206721241287347
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Introduction We report a case of early-onset lipemia retinalis secondary to the FLAG-Ida protocol in the treatment of acute myeloid leukemia (AML) in an 11-year-old girl.Case Report An 11-year-old patient, diagnosed with AML at four months old, experienced a relapse and was treated with the FLAG-Ida protocol (fludarabine, idarubicin, granulocyte-colony stimulating factor, and high-dose cytarabine). Prior to allogeneic stem cell transplantation, she underwent a pre-transplantation eye examination. The patient exhibited normal visual acuity in both eyes. Fundus examination revealed cream-white retinal vessels and a salmon-pink retina, indicative of grade 3 lipemia retinalis. Laboratory tests, normal before treatment initiation, showed significantly elevated serum cholesterol (727.6 mg/dL) and triglyceride (6015.6 mg/dL) levels post-treatment. After receiving fenofibrate, these levels decreased markedly, and the retinal vessels normalized on follow-up fundus examination.Conclusion Lipemia retinalis, characterized by creamy-white retinal vessels resulting from hypertriglyceridemia, can develop as a secondary condition to chemotherapy. Early detection and treatment of hyperlipidemia are crucial to prevent severe ocular and systemic complications. This case highlights the importance of monitoring lipid levels and conducting thorough ophthalmologic examinations in patients undergoing chemotherapy.
引用
收藏
页码:NP5 / NP9
页数:5
相关论文
共 50 条
  • [31] FLAG-IDA as frontline induction or salvage therapy for patients with high risk and/or relapsed or refractory acute myeloid leukemia (AML)
    Bhella, Sita
    Atenafu, Eshetu G.
    Schuh, Andre C.
    Minden, Mark D.
    Schimmer, Aaron David
    Gupta, Vikas
    Seftel, Matthew D.
    Alam, Naheed
    Lutynski, Andrzej
    Rydlewski, Anna
    Rostom, Amr
    Yee, Karen W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] High remission rate with the FLAG-IDA regimen in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML) patients up to 70 years old.
    Bernardi, M
    Ciceri, F
    Camba, L
    Peccatori, J
    Lunghi, F
    Milani, R
    Corradini, P
    Bregni, M
    BLOOD, 2002, 100 (11) : 337B - 337B
  • [33] Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia
    Dinardo, Courtney D.
    Jen, Wei-Ying
    Takahashi, Koichi
    Kadia, Tapan M.
    Loghavi, Sanam
    Daver, Naval G.
    Xiao, Lianchun
    Reville, Patrick K.
    Issa, Ghayas C.
    Short, Nicholas J.
    Sasaki, Koji
    Wang, Sa A.
    Mullin, Jillian K.
    Pierce, Sherry
    Bradley, Corey
    Borthakur, Gautam
    Maiti, Abhishek
    Alvarado, Yesid
    Pemmaraju, Naveen
    Ferrajoli, Alessandra
    Swaminathan, Mahesh
    Ohanian, Maro
    Abbas, Hussein A.
    Hammond, Danielle
    Burger, Jan
    Haddad, Fadi
    Montalban-Bravo, Guillermo
    Chien, Kelly
    Masarova, Lucia
    Yilmaz, Musa
    Jain, Nitin
    Andreeff, Michael
    Garcia-Manero, Guillermo
    Kornblau, Steven
    Ravandi, Farhad
    Jabbour, Elias
    Konopleva, Marina Y.
    Kantarjian, Hagop M.
    LEUKEMIA, 2025, : 854 - 863
  • [34] FLAG/FLAG-Ida Regimen in Secondary and Relapsed/Refractory Acute Myeloid Leukemia-Even in the Era of New Treatment Modalities Still a Significant Player
    Doma, Sasa Anzej
    Sever, Matjaz
    Jakos, Gorazd
    Podgornik, Helena
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (07)
  • [35] TREATMENT WITH FLAG-IDA OR FLAGO-IDA REGIMEN IN ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA. RETROSPECTIVE ANALYSIS OF THE PETHEMA AML REGISTRY
    Burgues, J.
    Montesinos, P.
    Martinez-Cuadron, D.
    Serrano, J.
    Fernandez, P.
    Rayon, C.
    Sayas, M.
    Barrios, M.
    Perez, C.
    Herrera, P.
    Martinez, M.
    Garcia, R.
    Gayoso, J.
    Perez-Encinas, M.
    Riaza, R.
    Prieto, J.
    Colorado, M.
    Amador, M.
    Moscardo, F.
    Sanz, M.
    HAEMATOLOGICA, 2013, 98 : 25 - 25
  • [36] FLAG-Ida, the possible breakthrough in the treatment of refractory acute myeloid leukemia in the context of hematopoietic stem cell transplantation: Single center experience
    Georgievski, B.
    Veljanovska, A. Pivkova
    Stavric, S. Genadieva
    Stojanoski, Z.
    Cadievski, L.
    Cevreska, L.
    BONE MARROW TRANSPLANTATION, 2015, 50 : 5608 - 5609
  • [37] FLAG-IDA Has Significant Activity As Frontline Induction or Salvage Therapy for Patients with High Risk and/or Relapsed or Refractory Acute Myeloid Leukemia (AML)
    Bhella, Sita D.
    Atenafu, Eshetu G.
    Schuh, Andre C.
    Minden, Mark D.
    Schimmer, Aaron D.
    Gupta, Vikas
    Seftel, Matthew D.
    Alam, Naheed
    Lutynski, Andrzej
    Rostom, Amr
    Rydlewski, Anna
    Yee, Karen
    BLOOD, 2014, 124 (21)
  • [38] EFFICACY OF THE FLAG-IDA REGIMEN AS FIRST LINE TREATMENT FOR MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM A SINGLE CENTER
    Bernardi, M.
    Tassara, M.
    Crotta, A.
    Messina, C.
    Peccatori, J.
    Assanelli, A.
    Clerici, D.
    Mastaglio, S.
    Ciceri, E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 279 - 279
  • [39] Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis
    Ofir Wolach
    Avraham Frisch
    Liat Shargian
    Moshe Yeshurun
    Arie Apel
    Vladimir Vainstein
    Yakir Moshe
    Shai Shimony
    Odelia Amit
    Yael Bar-On
    Yishai Ofran
    Pia Raanani
    Boaz Nachmias
    Ron Ram
    Annals of Hematology, 2022, 101 : 1719 - 1726
  • [40] Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis
    Wolach, Ofir
    Frisch, Avraham
    Shargian, Liat
    Yeshurun, Moshe
    Apel, Arie
    Vainstein, Vladimir
    Moshe, Yakir
    Shimony, Shai
    Amit, Odelia
    Bar-On, Yael
    Ofran, Yishai
    Raanani, Pia
    Nachmias, Boaz
    Ram, Ron
    ANNALS OF HEMATOLOGY, 2022, 101 (08) : 1719 - 1726